Elamipretide Boosts Spinal Cord Injury Recovery by Protecting Mitochondria

Spinal cord injury (SCI) is a devastating condition leading to permanent motor impairment due to severe secondary damage, including mitochondrial dysfunction, oxidative stress, and apoptosis (programmed cell death). These factors collectively impede neurological recovery, and the blood-brain barrier often limits effective drug delivery to the injury site. This study investigates whether Elamipretide (SS-31), a novel mitochondria-targeting peptide, can mitigate these issues and promote functional recovery after SCI.

Treatment with Elamipretide (SS-31) significantly improved neurological recovery compared to controls. The 3 mg/kg group showed a 2.5-fold increase in BBB scores by day 28 (from ~3.5 in control to ~8.8 in treated, p<0.001). Mitochondrial bioenergetics were markedly preserved, with ATP levels (the cell's energy currency) in the injured spinal cord increasing by 43% in the high-dose group (p<0.01). Furthermore, oxidative stress markers (e.g., malondialdehyde) were reduced by 35% (p<0.05), and neuronal apoptosis was decreased by 50% (p<0.001). The most significant finding was that Elamipretide (SS-31) at 3 mg/kg led to a 60% increase in synaptic density in the perilesional area and a 2.5-fold improvement in hindlimb motor function compared to untreated controls by day 28, indicating robust neural remodeling and functional restoration.